Tesaro Inc. (NASDAQ:TSRO) has received an average recommendation of “Buy” from the fifteen brokerages that are currently covering the company. Three analysts have rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $105.36.

A number of equities analysts have recently commented on the stock. Leerink Swann restated a “buy” rating on shares of Tesaro in a research note on Monday, June 6th. FBR & Co restated a “buy” rating on shares of Tesaro in a research note on Thursday, June 30th. SunTrust Banks Inc. restated a “buy” rating and set a $91.60 price objective on shares of Tesaro in a research note on Wednesday, September 14th. Zacks Investment Research upgraded shares of Tesaro from a “sell” rating to a “hold” rating in a research note on Tuesday, July 5th. Finally, Wedbush reiterated a “buy” rating on shares of Tesaro in a research note on Thursday, June 30th.

Shares of Tesaro (NASDAQ:TSRO) opened at 103.26 on Thursday. The firm’s 50-day moving average price is $92.62 and its 200-day moving average price is $63.23. The firm’s market capitalization is $5.30 billion. Tesaro has a 12-month low of $29.51 and a 12-month high of $108.27.

Tesaro (NASDAQ:TSRO) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.28) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.71) by $0.43. Tesaro had a negative net margin of 783.97% and a negative return on equity of 205.63%. The company earned $36.60 million during the quarter, compared to the consensus estimate of $4.98 million. During the same period in the prior year, the business posted ($1.51) EPS. Equities analysts predict that Tesaro will post ($7.33) earnings per share for the current fiscal year.

In other news, VP Jeffrey H. Hanke sold 29,166 shares of the firm’s stock in a transaction that occurred on Tuesday, August 30th. The shares were sold at an average price of $86.04, for a total transaction of $2,509,442.64. Following the transaction, the vice president now directly owns 29,166 shares of the company’s stock, valued at $2,509,442.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Jeffrey H. Hanke sold 12,500 shares of the firm’s stock in a transaction that occurred on Thursday, June 30th. The stock was sold at an average price of $74.35, for a total transaction of $929,375.00. Following the transaction, the vice president now directly owns 12,500 shares in the company, valued at $929,375. The disclosure for this sale can be found here. Insiders own 40.50% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in TSRO. Metropolitan Life Insurance Co. NY boosted its position in shares of Tesaro by 15.8% in the first quarter. Metropolitan Life Insurance Co. NY now owns 18,369 shares of the biopharmaceutical company’s stock worth $809,000 after buying an additional 2,500 shares during the period. Legal & General Group Plc boosted its position in shares of Tesaro by 29.9% in the first quarter. Legal & General Group Plc now owns 6,581 shares of the biopharmaceutical company’s stock worth $288,000 after buying an additional 1,514 shares during the period. Nuveen Asset Management LLC boosted its position in shares of Tesaro by 7.4% in the first quarter. Nuveen Asset Management LLC now owns 20,598 shares of the biopharmaceutical company’s stock worth $907,000 after buying an additional 1,412 shares during the period. Geode Capital Management LLC boosted its position in shares of Tesaro by 1.6% in the first quarter. Geode Capital Management LLC now owns 197,043 shares of the biopharmaceutical company’s stock worth $8,675,000 after buying an additional 3,018 shares during the period. Finally, Nicholas Investment Partners LP purchased a new position in shares of Tesaro during the first quarter worth about $914,000. 88.87% of the stock is currently owned by institutional investors.

About Tesaro

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

5 Day Chart for NASDAQ:TSRO

Receive News & Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related companies with MarketBeat.com's FREE daily email newsletter.